{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"The Kaplan-Meier estimate of event-free survival (EFS) along with their standard errors will be calculated using the SAS macro (bmacro251-Excel2007\\\\kme) available in the Department of Biostatistics at St. Jude, where EFS = min (date of last follow-up, date of relapse, date of graft failure, date of death due to any cause) - date of transplant, and all participants surviving at the time of analysis without events will be censored. The number of participants who did not experience any of these events through one year post-transplant is given.","groups":[{"description":"Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.\n\nCyclophosphamide: Given intravenously (IV)\n\nFludarabine: Given IV\n\nG-CSF: Given IV or subcutaneously (SQ)\n\nInterleukin-2: Given SQ\n\nMelphalan: Given IV\n\nThiotepa: Given IV\n\nRituximab: Given IV\n\nNatural killer cell therapy: Given IV\n\nT-cell depleted HPC transplant: T-cell depleted hematopoietic stem cells will be infused on day 0.\n\nCD45RA-depleted HPC transplant: CD45RA depleted stem cells will be infused on day 1.","id":"OG000","title":"Participants"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"one year post transplantation","title":"Event-free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"participants"}